CAR-T cell therapies
Oncology· 5 reviewed drugs· 6971 cited findings behind them
What the regulatory reviews cover
This library includes several CAR-T cell therapies that have undergone regulatory review. Breyanzi is indicated for adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor, and for 3rd line + follicular lymphoma (FL). Tecartus is indicated for adult patients with relapsed or refractory MCL after two or more lines of systemic therapy including a BTK inhibitor, and for relapsed or refractory B-ALL. Abecma and Carvykti are indicated for adult patients with relapsed and refractory multiple myeloma (RRMM) who have received specific prior therapies. Aucatzyl is indicated for adult patients 26 years of age and above with relapsed or refractory (r/r) B cell precursor acute lymphoblastic leukaemia (B ALL).
Regulatory review documents report various outcomes for these therapies. For Breyanzi, the ORR for brexucabtagene autoleucel in R/R MCL (ZUMA-2 study) was 91% compared to an ORR for ibrutinib in R/R MCL of 72%. Tecartus showed an ORR in ZUMA-2 after failing BTK inhibitor of 86. Abecma demonstrated an Overall response rate (ORR) in Study CRB-401 of 86%. Carvykti reported an Overall Response Rate (ORR) of 87.8%. Aucatzyl had an Overall Remission Rate (CR+CRi) of 75.0. It is important to note that these figures are derived from different trials and are not directly comparable head-to-head.
The drugs — one cited result each
| Breyanzi Bristol-Myers Squibb Company | ORR for brexucabtagene autoleucel in R/R MCL (ZUMA-2 study): 91% Breyanzi EMA EPAR variation a, p.11 |
| Tecartus Gilead Sciences, Inc. | ORR in ZUMA-2 after failing BTK inhibitor: 86 Tecartus EMA EPAR public assessment, p.8 |
| Abecma Bristol-Myers Squibb Company | Overall response rate (ORR) in Study CRB-401: 86% Abecma EMA EPAR public assess, p.8 |
| Carvykti Johnson & Johnson | Overall Response Rate (ORR): 87.8% Carvykti EMA EPAR public assessment repo, p.7 |
| Aucatzyl Autolus | Overall Remission Rate (CR+CRi): 75.0 Aucatzyl EMA EPAR public assessment report (EMEA/H, p.51 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.